Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...

Insights from ECTRIMS 2025, including anticipated presentations, key takeaways, and how emerging research on DMTs in RRMS may affect patient care.

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Having inactive secondary progressive multiple sclerosis can be confusing. Relapses may stop, but symptoms persist. Get ...

New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...